v3.26.3
STOCKHOLDERS’ EQUITY
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 10 – STOCKHOLDERS’ EQUITY

 

Designation of Series B Preferred Stock

 

Effective June 26, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series B Preferred Stock (the “Series B Preferred Stock”) with the Secretary of the State of Delaware that designated 787,754 shares of the Company’s authorized and unissued preferred stock as convertible Series B Preferred Stock at a par value of $0.00001 per share.

 

Holders of the Series B Preferred Stock are not entitled to receive dividends and do not have redemption or voting rights. Furthermore, the Series B Preferred Stock does not have a liquidation preference. Shares of Series B Preferred Stock are automatically convertible into shares of the Company’s common stock at a ratio of four shares of common stock for each share of Series B Preferred Stock upon stockholder approval of such conversion.

 

As of September 30, 2026 and December 31, 2025, there were 15,759 issued and outstanding shares of Series B Preferred Stock.

 

Designation of Series X Preferred Stock

 

On July 25, 2024, the Company revoked the authorization to issue shares of the Company’s Series A Preferred Stock, par value $0.00001 per share (the “Series A Preferred Stock”) and concurrently authorized the issuance of up to 9,211,246 shares of the Series X Preferred Stock, a then new class of preferred stock. As consideration for the Scienture Merger, the shares of Scienture common stock issued and outstanding immediately prior to the “Effective Time” of the mergers were converted into the right to receive, in the aggregate, (i) 11,661 shares of the Company’s common stock and (ii) 6,826,753 shares of the Company’s Series X Preferred Stock, each share of which was convertible into 1/25th of a share of common stock (as adjusted for the Reverse Stock Split).

 

In September 20, 2024, all previously issued shares of Series X Preferred Stock were converted into a total of 273,070 shares of common stock. As such, there were no issued and outstanding shares of Series X Preferred Stock as of September 30, 2026, and December 31, 2025.

 

 

Common Stock

 

During the nine months ended September 30, 2026, the Company issued 34,664 restricted shares of common stock for services, as described below. In September 2026, the Company sold 128,059 shares of common stock through Maxim Group LLC under its at-the-market offering program for proceeds of $524,557, of which $484,995 was recorded as a subscription receivable as of September 30, 2026. The subscription receivable was collected in full on October 6, 2026. During the year ended December 31, 2025, the Company issued an aggregate of 284,145 shares of common stock for net proceeds of $9,008,199.

 

Restricted Common Stock

 

As of September 30, 2026 and December 31, 2025, the Company had 75,262 and 40,600 unvested restricted shares of common stock outstanding, respectively. During the three months ended June 30, 2026, the Company issued 17,331 restricted shares of common stock to certain executive officers of the Company and Scienture, LLC for services rendered, with an aggregate grant date fair value of $173,332. These shares vest in June 2029 (13,332 shares) and June 2030 (3,999 shares), and the related stock-based compensation expense recognized during the three and nine months ended September 30, 2026 was nominal. During the three months ended September 30, 2026, the Company issued an additional 17,331 restricted shares of common stock to the same executive officers for services rendered, with an aggregate grant date fair value of $173,310. These shares vest in September 2029 (13,332 shares) and September 2030 (3,999 shares). The Company recorded stock-based compensation expense of $126,948 and $332,725 in the consolidated statements of operations for the three and nine months ended September 30, 2026, respectively. Unrecognized stock compensation outstanding on these grants was $752,910 as of September 30, 2026.

 

Equity Compensation Awards

 

Each independent member of the Company’s board of directors is to receive an annual grant of restricted common stock of the Company equal to $55,000 in value on April 1st of each year (or such date thereafter as the awards are approved by the board of directors), and valued on such same date, based on the closing sales price on such date (or the first business day thereafter), which restricted stock awards will vest at the rate of 1/4th of such awards over the following four calendar quarters, subject to such directors continued service to the Company.

 

The board of directors and the Company’s stockholders approved an amendment to the Second Amended and Restated 2019 Equity Incentive Plan (the “Plan”), which increased the available shares under the Plan to 200,000 shares of the common stock.